Ultragenyx制药 RARE 深 沪
等待开盘 08-21 09:30:00 美东时间
29.27
+0.150
+0.52%
华盛通- 最 高29.50
- 今 开29.02
- 成交量 56.03万股
- 最 低 29.00
- 昨 收 29.12
- 总市值 27.67亿
- 52周最高 60.37
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 25.81
- 委 比 89.09%
- 总股本 9454.20万
- 历史最高 179.647
- 量 比 0.51
- 振 幅 1.72%
- 历史最低 25.81
- 每 手 1
- 风险率 8.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mereo BioPharma signs licensing deal with privately held āshibio
Mereo BioPharma (NASDAQ:MREO) signed an exclusive licensing deal with privately held biotech āshibio, for the antibody therapy vantictumab, intended to treat autosomal dominant osteopetrosis type 2. A...
08-19 21:43
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
Ultragenyx Pharmaceutical Inc. announced the initiation of a rolling submission of a Biologics License Application (BLA) to the FDA for DTX401 AAV gene therapy, intended to treat Glycogen Storage Disease Type Ia (GSDIa). The company has already submitted non-clinical and clinical modules and plans to complete the full BLA, including the chemistry, manufacturing, and controls (CMC) module, by the fourth quarter of 2025. The BLA includes 96-week da...
08-18 12:00
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
What to Expect from Kymera Therapeutics's Earnings
Kymera Therapeutics (NASDAQ:KYMR) is gearing up to announce its quarterly earni...
08-08 23:01
8 Analysts Assess Ultragenyx Pharmaceutical: What You Need To Know
Across the recent three months, 8 analysts have shared their insights on Ultrag...
08-07 06:01
Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $105
Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $112 to $105.
08-06 22:17
USA Rare Earth to Present at the Canaccord Genuity 45th Annual Growth Conference
USA Rare Earth, Inc. announced that its Chief Financial Officer, W. Robert Steele, will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 3:30pm Eastern Time. The presentation will be available on the company’s investor website, with a replay accessible for 90 days. USA Rare Earth is building a domestic rare earth magnet production supply chain and is constructing a manufacturing facility in Oklahoma. The compa...
08-06 11:01
Ultragenyx Pharmaceutical Affirms FY2025 Sales Guidance of $640.00M-$670.00M vs $653.27M Est
Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2025 sales outlook from $640.00 million-$670.00 million to $640.00 million-$670.00 million vs $653.27 million estimate.
08-06 04:02
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Recursion Pharmaceuticals Earnings Preview
Recursion Pharmaceuticals (NASDAQ:RXRX) is gearing up to announce its quarterly...
08-05 01:05
